Megavitamin and Dietary Treatment in Schizophrenia: A Randomised, Controlled Trial

  title={Megavitamin and Dietary Treatment in Schizophrenia: A Randomised, Controlled Trial},
  author={K. Vaughan and N. Mcconaghy},
  journal={Australian and New Zealand Journal of Psychiatry},
  pages={84 - 88}
Objective: The aim of this study was to assess the efficacy of adjunctive megavitamin and dietary treatment in schizophrenia. Method: Arandom allocation double-blind, controlled comparison of dietary supplement and megavitamin treatment, and an alternative procedure was given for 5 months to 19 outpatients with a diagnosis of schizophrenia. In addition to usual follow-up, the experimental group received amounts of megavitamins based on their individual serum vitamin levels plus dietary… Expand

Tables and Topics from this paper

Broad-spectrum micronutrient formulas for the treatment of psychiatric symptoms: a systematic review
Despite positive preliminary findings, there are less data available to support efficacy of micronutrient formulas in treating bipolar disorder, attention deficit-hyperactivity disorder and substance abuse/dependence and no clinical trials have been done with clinically depressed or anxious patient samples, psychosis or eating disorders. Expand
Fatty acid and vitamin interventions in adults with schizophrenia: a systematic review of the current evidence
There were more positive findings in support of fatty acid supplementation compared with vitamin supplementation in the context of specific intervention features and clinical outcomes, but investigations of both supplementation modalities were limited by relatively small study sample sizes, short study duration. Expand
Effects of vitamins, fatty acids, minerals, and other dietary supplements on schizophrenic symptoms in people with schizophrenia
It is difficult to draw strong conclusions about the effects of vitamins, minerals and other dietary supplements on symptoms of schizophrenia, as the evidence is of low or very low quality. Expand
Natural Medicines for Psychotic Disorders
In 110 randomized controlled trials, evidence was found for glycine, sarcosine, N-acetylcysteine, some Chinese and ayurvedic herbs, ginkgo biloba, estradiol, and vitamin B6 to improve psychotic symptoms when added to antipsychotics. Expand
Aberrant folate status in schizophrenic patients: What is the evidence?
It is found that none of the 7 case-control studies included in this review explicitly reported on all critical factors in the assessment of folate, and only three studies found lower plasma folate levels more frequently in patients with schizophrenia compared to controls. Expand
Homocysteine metabolism and risk of schizophrenia
The results of a meta-analysis of the current literature give support to the conclusion presented in the previous report that elevated tHcy concentration is a risk factor for schizophrenia. Expand
Treatment-refractory schizophrenia: what is it and what has been done about it?
There has been a veritable explosion of research conducted for interventions that may be advantageous for the management of treatment-refractory schizophrenia. After a discussion of how to defineExpand
Maternal Nutritional Deficiencies and Schizophrenia
The evidence from the work on this particular risk factor is brought together, suggesting that early alterations in the ontogeny of dopamine pathways could be a convergent mechanism operating within many diverse epidemiologically informed developmental risk factors. Expand
Nutrition interventions in populations with mental health conditions: a scoping review.
Though most interventions led to statistically significant improvements, trials were heterogeneous for targeted mental disorders, nutrition interventions, and outcomes assessed, and further research from robust and clinically relevant trials is required. Expand
The place of anticonvulsants and other putative mood stabilisers in the treatment of bipolar disorder.
  • P. Mitchell
  • Medicine
  • The Australian and New Zealand journal of psychiatry
  • 1999
This paper critically evaluates the current evidential basis for claims for the efficacy of these compounds in bipolar disorder and some of the newer anticonvulsants and the atypical antipsychotics. Expand


Nicotinic acid therapy in chronic schizophrenia.
The value of nicotinic acid in the treatment of chronic schizophrenic patients is doubtful and two of 14 experimental subjects showed marked improvement in their behavior; 4 others showed minimal to moderate improvement; the remaining subjects either showed no change or mild deterioration of their conditions. Expand
Nicotinic Acid in the Prevention and Treatment of Methionine-Induced Exacerbation of Psychopathology in Schizophrenics *
Nicotinic acid failed to prevent by prior administration or to relieve by subsequent administration, the methionine-tranylcypromine-induced exacerbation of psychopathology, and the possibility of a toxic psychosis due to the metabolite, methamphetamineionine sulfoximine, must be seriously considered. Expand
A search for responders to niacin supplementation.
It is suggested that patients with dissociative psychosis and a history of interpersonal participation may respond well with high-dosage niacin as supplementary to other medication and treatment. Expand
Nicotinic Acid in the Treatment of Schizophrenias: Canadian Mental Health Association Collaborative Study Progress Report II *
A l'origine, le terme “megavitaminotherapie” signifiait l'usage de fortes doses de vitamine B3 (acide nicotinique ou nicotinamide) d'acide ascorbique, la pyrido. Expand
The effects of nicotinic acid, nicotinamide, and placebo on the chronic schizophrenic.
Analysis of the results failed to show any evidence that the treatments were influencing the patients, and massive doses of nicotinic acid and nicotinamide were tested on the chronic schizophrenic together with an inert placebo. Expand
Psychosocial functioning and subjective experience in schizophrenia.
This study examines the relationship between psychosocial functioning and subjective experience in 193 individuals diagnosed with schizophrenia or schizoaffective disorder according to Research Diagnostic Criteria to suggest a primary and pervasive relationship between the disorder-related variables and subjective experienced and a secondary and less pronounced relationship between functional status variables and objective experience. Expand
Orthomolecular Psychiatry
Biochemical and genetic arguments support the idea that orthomolecular therapy, the provision for the individual person of the optimum concentrations of important normal constituents of the brain, may be the preferred treatment for many mentally ill patients. Expand
The Brief Psychiatric Rating Scale
The Brief Psychiatric Rating Scale was developed to provide a rapid assessment technique particularly suited to the evaluation of patient change. Sixteen symptom constructs which have resulted fromExpand
Letter to the editor
I am:gra te fu l to Drs. Boyd and Merskey for their elucidation of the discrepancy in the u s e of pain descriptors emerging ~ o m a comparisou of their survey (Pain, 5, 1978, 1--3) and my own (Pain,Expand
Diagnosis of allergy by an in-vitro test for allergen antibodies.
The results strongly support the hypothesis that reagins belong to the immunoglobulin class IgND, provisionally called IgND. Expand